Imbria Pharmaceuticals

aid: imbria-pharmaceuticals
name: Imbria Pharmaceuticals
description: Imbria Pharmaceuticals is a private, clinical-stage biopharmaceutical company based in the Boston area that is
  developing novel cardiovascular therapies targeting cardiac energy metabolism. Its lead candidate, ninerafaxstat, is a first-in-class
  partial fatty acid oxidation (pFOX) inhibitor designed to shift myocardial substrate utilization toward glucose oxidation,
  generating more ATP per unit of oxygen consumed and improving cardiac metabolic efficiency without affecting heart rate,
  rhythm, ejection fraction or blood pressure. Ninerafaxstat is in the global FORTITUDE-HCM Phase 2b trial (NCT07023614) for
  symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), which has no approved treatments, and holds FDA Orphan Drug
  Designation for that indication; a Phase 2b in cardiometabolic HFpEF is planned. The company is backed by RA Capital, SV
  Health Investors, Deep Track Capital, Catalio Capital Management, AN Ventures and Cytokinetics. Imbria is a therapeutics
  developer, not a software vendor, and publishes no public API, developer portal, SDK or machine-readable API contract.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://imbria.com/wp-content/uploads/2025/09/imbria_logo-1.svg
url: https://raw.githubusercontent.com/api-evangelist/imbria-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
specificationVersion: '0.20'
created: '2026-08-22'
modified: '2026-08-22'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Cardiovascular
- Clinical Trials
- Drug Development
- Healthcare
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/imbria-pharmaceuticals-domain-security.yml
- type: Website
  url: https://imbria.com/
- type: About
  url: https://imbria.com/our-story/
- type: Blog
  url: https://imbria.com/investors-media/press-releases/
- type: BlogRSS
  url: https://imbria.com/feed/
- type: Support
  url: https://imbria.com/contact/
- type: TermsOfService
  url: https://imbria.com/terms-of-use/
- type: PrivacyPolicy
  url: https://imbria.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/imbria/
- type: LLMsTxt
  url: llms/imbria-pharmaceuticals-llms.txt
x-enrichment:
  date: '2026-08-22'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Imbria Pharmaceuticals is a private clinical-stage biopharma developing ninerafaxstat for cardiovascular disease;
    imbria.com is a WordPress marketing site whose only machine-readable surface is the default WordPress core REST API at
    /wp-json/, and every developer-program path probed (/developers, /docs, /api, /openapi.json, /graphql, /llms.txt, /apis.json
    and eight /.well-known/ documents) returned the site's standard 404.
  evidence:
  - url: https://imbria.com/developers
    status: 404
  - url: https://imbria.com/openapi.json
    status: 404
  - url: https://imbria.com/.well-known/api-catalog
    status: 404
  - url: https://imbria.com/.well-known/agent-card.json
    status: 404
  - url: https://imbria.com/wp-json
    status: 200
  - url: https://github.com/imbria
    status: 404
  checked: '2026-08-22'